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Maintenance of the EBV-specific CD8+ TCRαβ
repertoire in immunosuppressed lung transplant
recipients
Thi HO Nguyen1,8, Nicola L Bird1,8, Emma J Grant1,2, John J Miles3,4, Paul G Thomas5, Tom C Kotsimbos6,8,
Nicole A Mifsud6,7,8 and Katherine Kedzierska1,8
Epstein-Barr virus (EBV) is one of the most common viruses in humans, capable of causing life-threatening infections and
cancers in immunocompromised individuals. Although CD8+ T cells provide key protection against EBV, the persistence and
dynamics of specific T-cell receptor (TCR) clones during immunosuppression in transplant patients is largely unknown. For the
first time, we used a novel single-cell TCRαβ multiplex-nested reverse transcriptase PCR to dissect TCRαβ clonal diversity within
GLCTLVAML (GLC)-specific CD8+ T cells in healthy individuals and immunocompromised lung transplant recipients. The GLC
peptide presented by HLA-A*02:01 is one of the most immunogenic T-cell targets from the EBV proteome. We found that the
GLC-specific TCRαβ repertoire was heavily biased toward TRAV5 and encompassed five classes of public TCRαβs, suggesting
that these clonotypes are preferentially utilized following infection. We identified that a common TRAV5 was diversely paired
with different TRAJ and TRBV/TRBJ genes, in both immunocompetent and immunocompromised individuals, with an average of
12 different TCRαβ clonotypes/donor. Moreover, pre-transplant GLC-specific TCRαβ repertoires were relatively stable over 1 year
post transplant under immunosuppression in the absence or presence of EBV reactivation. In addition, we provide the first
evidence of early GLC-specific CD8+ T cells at 87 days post transplant, which preceded clinical EBV detection at 242 days in an
EBV-seronegative patient receiving a lung allograft from an EBV-seropositive donor. This was associated with a relatively stable
TCRαβ repertoire after CD8+ T-cell expansion. Our findings provide insights into the composition and temporal dynamics of the
EBV-specific TCRαβ repertoire in immunocompromised transplant patients and suggest that the early detection of EBV-specific
T cells might be a predictor of ensuing EBV blood viremia.
Immunology and Cell Biology (2017) 95, 77–86; doi:10.1038/icb.2016.71
Epstein-Barr virus (EBV), a member of the human herpesvirus family,
infects ~ 95% of the developed world’s population. Transmission
during infancy occurs via saliva and is generally asymptomatic.
However, adolescents have a higher chance of developing acute
infectious mononucleosis, known as glandular fever, compared with
the general population. In Western countries, the estimated
incidence rate of infectious mononucleosis is 320–370/1 00 000 per
annum in adolescents (15–19 years) compared with a general rate
of 45/1 00 000 per annum.1,2 EBV causes opportunistic infection
in immunocompromised individuals, including HIV-infected and
post-solid organ transplant patients undergoing maintenance
immunosuppression.3,4 CD8+ T cells have a crucial role in controlling
EBV infection by providing persistent immunosurveillance. One of
the most immunogenic T-cell targets from EBV is the GLCTLVAML
(GLC) peptide derived from the lytic BMLF1 protein (residues
280–288). GLC is restricted to the HLA-A*02:01 allele, the most
prevalent HLA-I molecule in Caucasians, with a frequency of 35–40%.
In the peripheral blood of healthy EBV-positive individuals, circulating
GLC-specific CD8+ T cells constitute between 0.5–2.2% of total CD8+
T cells during latent infection. During primary infection and in the
elderly, this single antigen-specific population can increase to up to
10% of total circulating CD8+ T cells.5,6
GLC-specific CD8+ T cells are characterized by a highly skewed
T-cell receptor (TCR) repertoire, with identical (public) or
near-identical TCRs within and between individuals.7–10 This
repertoire is relatively stable over time.11,12 TCRs that bind the
A2-GLC complex are composed of membrane-bound alpha (α) and
beta (β) chains generated from the random recombination of variable
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(V), diversity (D), joining (J) and constant (C) genes. Further diversity
is created by pairing the α and β chains with nucleotides additions
and deletions between the V(D)J junctions specifically at the
complementary-determining region 3 (CDR3).13 Given the potential
TCR diversity of 41015 thymic14 and 4107 peripheral different
TCR combinations,15 it is surprising that the GLC-specific CD8+
TCR repertoire is biased to an average of ~ 9 unique clonotypes
(range 3–20) per individual.7,16
Structural studies between the TCR, peptide (p) and MHC
(reviewed)17,18 have provided insights into how TCRs are selected to
preferentially bind to their cognate pMHC and thus shape the overall
immune response (reviewed).10 The most abundant TCR clonotype
within GLC-specific CD8+ T cells has been identified,7–9,19 named
AS01.20 AS01 consists of TRAV5/TRAJ31/TRBV20-1/TRBJ1-2 genes
with CDR3α-DNNARL and CDR3β-RDGTGNGY sequences.
Structurally and thermodynamically, AS01-TCR was preferentially
selected by drawing on germline residues to uniquely engage the
GLC/HLA-A*02:01 complex.20
Here, we use a new unbiased, single-cell TCRαβ multiplex-nested
reverse transcriptase PCR21,22 to quantitatively dissect clonotypic
TCRαβ diversity within the GLC-specific CD8+ T cells and track the
abundance of the AS01 clonotype in healthy individuals directly
ex vivo. Furthermore, we explored the temporal dynamics of the
GLC-specific CD8+ TCRαβ repertoire in a longitudinal cohort of lung
transplant recipients under immunosuppressive conditions before and
after EBV exposure. Extending previous studies, we observed that the
GLC-specific CD8+ T-cell response was heavily dominated by TRAV5,
yet was diversely paired with other TRAJ genes and TRBV/TRBJ genes,
in both immunocompetent and immunocompromised individuals,
with an average of 12 different TCRαβ clonotypes per individual
(range 7–22 clonotypes). Our paired TCRαβ sequence analysis
revealed four additional prominent public clonotypes, in addition to
AS01, that were shared between donors. This bias had previously been
underestimated because of the lack of paired TCRαβ analysis, low
number of examined donors and/or limited cloning methodologies.
In the lung transplant cohort, we report for the first time, the
detection of preclinical GLC-specific CD8+ T cells, using
tetramer-associated magnetic enrichment (TAME), before the
detectable onset of primary EBV infection (155 days earlier) in an
EBV-seronegative patient, who received an EBV-seropositive donor
lung allograft. Most strikingly, these preclinical GLC-specific CD8+
T cells exhibited prominent TRAV5 bias and encompassed public
TCR clonotypes identified earlier in the healthy donors, suggesting
that TCRαβ repertoires may have been genetically favorable prior
to detectable viremia based on viral load titers and perhaps
antigenic exposure. Importantly, the GLC-specific CD8+ TCRαβ
repertoires within both EBV-seropositive and EBV-seronegative lung
transplant recipients remained stable over time under immunosup-
pressive conditions in either the presence or absence of EBV-related
clinical and viral titer events.
RESULTS
GLC-specific T cells exhibit prominent TRAV5 gene bias with
diverse TCRαβ repertoires in healthy donors
Historically, studies investigating GLC-specific CD8+ TCR repertoires
to identify the dominant AS01-TCR used extensive cloning
methodologies,8,9 bulk sorting of GLC-specific CD8+ T cells for total
mRNA9 or sequencing of individual CDR3α and/or CDR3β gene
segments.7,19 Here, we quantitatively characterized the GLC-specific
TCR repertoire using a broader unbiased TCRαβ paired analysis,21
whereby TCRαβ transcripts from a single cell were simultaneously
amplified following reverse transcriptase PCR and multiplex-nested
PCR.22 GLC-specific CD8+ T cells from ex vivo peripheral blood
mononuclear cell (PBMC) of ‘healthy’ donors (that is, EBV-positive
donors with no evidence of EBV reactivation) were used for TCRαβ
analysis (Figure 1a).
The ex vivo GLC-specific CD8+ TCRαβ repertoire in healthy donors
was dominated by TRAV5, representing 79.3–93.8% of the total TCRa
repertoire. TRBV usage was more diverse between donors with
TRBV14, TRBV20-1 and TRBV29-1 being the most frequently
deployed genes (Figure 1b). Interestingly, paired TCRαβ analysis
revealed that the three most dominant TRBV genes (TRBV14,
TRBV20-1 and TRBV29-1) were preferentially paired with TRAV5,
representing 58.8–93.8% of collective pairing (Figure 1c).
On average, the GLC-specific CD8+ TCRαβ repertoire consisted
of 10 TCRαβ clonotypes (ranged 7–12) per individual. Paired
TCRαβ clonotypes were grouped into five ‘classes’ comprising of
TRAV5 paired with dominant TRBV genes (Type A-C), other
TRAV5 clonotypes (Type D) and non-TRAV5 clonotypes (Type E)
(Figure 1d). In a pooled analysis, 49% of all TRAV5-bearing
clonotypes were paired with TRAJ31 (Type A-B; Figure 1d) with
identical (40/43 cells) or nearly identical (3/43 cells) CDR3α sequences
to the public AS01-TCR (DXNARL, where ‘X’ denotes amino-acid
differences to the consensus sequence). In addition, these
TRAV5/TRAJ31 clonotypes were paired with the public TRBV20-1
gene, but were not necessarily biased toward TRBJ1-2 (Type A;
Figure 1d) and showed less similarity to AS01’s CDR3β sequence
(RXXXGNGY). Rather, 450% clonotypes within the TRAV5/
TRAJ31/TRBV20-1 group contained the TRBJ1-3 gene (58%, Type
B; Figure 1d). TRAV5 was also paired with the TRBV29-1/TRBJ1-4
genes but had variable CDR3α sequences and TRAJ gene usage
(Type C; Figure 1d). Individually, 2/3 donors showed the most
dominant pairing of TRAV5 with TRBV14 (D1: 41.2% and D3:
54.5%), whereas donor D2 had 61.8% of their GLC-specific
TCR repertoire having a Type B pairing (TRAV5/TRAJ31/
TRBV20-1/TRBJ1-3). Hence, type A and type B pairings may not
necessarily be the most dominant TCR deployment across all
individuals. Nevertheless, our paired single-cell analysis indicated a
striking TRAV5 bias despite a highly diverse GLC-specific TCRαβ
response in healthy EBV-positive donors.
GLC-specific TCRαβ repertoires in EBV-positive lung transplant
patients with no detectable EBV reactivation are stable over time
We next examined whether similar TRAV5 bias was observed in
clinical settings, and in particular, whether TCRαβ repertoires
remained stable under immunosuppressive therapy following lung
transplantation. EBV-positive patients Tx98 and Tx111 received
bilateral lung allografts from EBV-negative donors and experienced
no episodes of EBV reactivation, as clinically indicated or by viral load
testing during the 12–13 months of follow-up post transplantation.
Owing to a limited number of patients’ cells, PBMC from Tx98 and
Tx111 were expanded for TCRαβ analysis (Figure 2a). Overall, the
GLC-specific TCRαβ repertoire from patient Tx98 was dominated by
TRAV5, which represented 46% of TCRαβ sequences (n= 133).
Clonotypes D, E, F and G bearing near-identical TRAV5/TRAJ31/
TRBV20-1/TRBJ1-2 TCR sequences were present at pre-transplant
(39%), which persisted after transplantation (21–34%) (Figures 2b
and d). In addition, we observed another dominant non-TRAV5 TCR
comprising TRAV16/TRAJ48/TRBV/TRBJ genes (Clonotype J)
present at pre-transplant (18%), and observed in similar frequencies
throughout the follow-up period (22–26%). The majority of dominant
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Figure 1 TCRαβ repertoire of peripheral blood CD8+ T cells directed at the HLA-A*02:01-restricted EBV-GLC epitope in healthy individuals. Ex vivo stained
GLC-specific CD8+ T cells from healthy donors D1-D3 were single-cell sorted for TCRαβ analysis. Representative FACS plots (a) of ex vivo detected GLC+
CD8+ T cells. Cells were gated on live CD3+ T cells to compare the tetramer staining of CD8+ T cells against the background staining of CD8− T cells.
Percentages are based on gated CD8+ T-cell population. Percentages of GLC+CD8+ T cells following in vitro expansion are shown in brackets. Frequency
(b) of TRAV and TRBV gene usage for D1-3. Paired TRAV-TRBV clonotype frequencies are shown in c. Clonotypes A-E (d) were first grouped according to
their TRAV5 gene usage followed by their pairing to TRAJ, TRBV and TRBJ genes to identify publicly paired motifs. Abbreviations: ND, not determined;
X, different amino acid; *n, any number of amino acids.
EBV-specific CD8+ TCRαβ repertoires
THO Nguyen et al
79
Immunology and Cell Biology
Figure 2 Longitudinally stable GLC-specific TCRαβ repertoire in EBV-positive lung transplant recipients. GLC-tetramer+CD8+ T cells were single-cell sorted for
TCRαβ analysis following in vitro expansion. Longitudinal dot plots (a) of expanded GLC+CD8+ T cells from patient Tx111. Frequency (b) of paired
GLC-specific CD8+ CDR3αβ repertoires pre- and post transplant. Pie chart area shaded in red represent TRAV5 clonotypes. Percentage of TCRαβ clonotypes
shared compared with Pre-transplant (bar graph, left y axis) and SDI values (line graph, right y axis) are shown in c. Frequencies of GLC+CD8+ T cells
following expansion and clonotype details are listed in d.
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(D, J, K and L) and subdominant clonotypes (A, C and E) were
observed pre- and post transplant (Figures 2b and d).
Similarly, the GLC-specific TCRαβ repertoire from patient Tx111
was relatively stable from pre-transplant to 13 months post transplant,
with the exception of clonotypes L and M, which emerged at 8.5 and
13 months, respectively (Figures 2b and d). Unexpectedly, the public
AS01-TCRαβ was not observed in the GLC-specific TCRαβ repertoire
from patient Tx98 and it was only detected once in a pre-transplant
sample for Tx111 (clonotype F), even though the overall GLC-specific
TCRαβ repertoire of patient Tx111 was dominated by TRAV5
(75%, n= 135). Moreover, the most dominant TCRαβ in Tx111 was
the pairing of TRAV5/TRAJ37 with TRBV29-1/TRBJ1-4 (clonotype
A). Near-identical TRAV5/TRAJ37/TRBV29-1/TRBJ1-4 TCRs were
also observed in patient Tx98 and healthy donor D3.
Analysis of clonotype sharing revealed that477% common TCRαβ
clonotypes (range 77.1–87.5%) were used for Tx98 at any time
after the transplant and immunosuppression, whereas the TCRαβ
clonotypes sharing was between 72.7 and 96.8% for Tx111 (Figure 2c).
These results demonstrate a high degree of conservation of TCRαβ
clonotypes during the standard post-lung transplant immuno-
suppression. Similarly, the Simpson Diversity Index (SDI) was stable
at each time point for patients Tx98 and Tx111 from pre-transplant
to post transplant (range 0.80–0.85 and 0.67–0.82, respectively;
Figure 2c), which measures the richness (distinct numbers of
clonotypes) and evenness (distribution of clonotypes) of the TCRαβ
clonotypic repertoires.
Collectively, GLC-specific CD8+ T-cell responses were biased for
TRAV5 in two lung transplant recipients, although to a lesser extent
when compared with the healthy donors. Importantly, in the absence
of detectable EBV reactivation, the GLC-specific TCRαβ repertoires
remained stable over time under immunosuppressive conditions.
Detection of GLC-specific T cells prior to clinical primary EBV
infection in EBV-negative lung transplant recipient receiving an
EBV-positive allograft
To determine whether GLC-specific CD8+ T cells were biased for
TRAV5 before antigen encounter or skewed toward TRAV5 usage
after detectable EBV blood viremia, we examined GLC-specific CD8+
T cells in an EBV-negative lung transplant patient (Tx101) receiving
an EBV-positive allograft prior to development of the blood EBV
viremia. Using novel TAME methodology, we have identified naive
GLC-specific CD8+ T-cell precursors in cord blood.23 However, which
clonotypes are recruited has not been investigated by tracking the
same individual before and after EBV clinical diagnosis.
The first clinical indication of EBV infection in patient Tx101 was
corroborated with a viral load titre of 20 000 copies per ml in the
blood on day (d)242 post transplant following routine clinical follow-
up for primary EBV-mismatched patients. EBV viral loads were
negative on days 33, 70 and 87. Continuing low levels of viremia
were detected in the blood until d376 before a massive titre peak on
d461 (2 500 000 copies per ml; Figure 3). Throughout the follow-up
period (until day 1,860), patient Tx101 had repeated episodes of high
EBV reactivation events based on viral load titers, which aligned with
clinical manifestations, including upper respiratory tract infection, sore
throat, malaise, nasal congestion, muscle aches/pain and severe
lethargy. Symptoms were further exacerbated and prolonged owing
to a secondary bacterial infection. Antiviral therapy with oral
valganciclovir (900 mg daily) was implemented for 6 months post
transplant as the patient was a primary EBV mismatch, but continued
on owing to viral detection and clinical symptoms. EBV serology
results showed that the patient was immunoglobulin (Ig)M-negative/
IgG-negative on d87 post transplant. The only other available EBV
serology test result was on day 519, which was IgM-negative and IgG-
positive for EBV.
GLC-specific CD8+ T cells were expanded from PBMC
(~4–8× 106) at pre-transplant and on d32, d185, d299 and d472 post
transplant with A2-GLC-tetramer+ frequencies of 0.37, 0.10, 0.90, 4.80
and 33.00% based on the CD8+ T-cell population (Figure 3).
GLC-specific TCRαβ analysis was successfully performed on d185,
d299, d472 post transplant, which had readily detectable tetramer+
CD8+ T-cell populations and sufficient T-cell numbers for single-cell
sorting. At pre-transplant and d32, insufficient T-cell numbers
following T-cell expansion and negligible tetramer+ frequencies
precluded cell sorting and TCR analysis. Nevertheless, expanded
GLC-specific CD8+ T-cell populations from the blood were detected
on d185 (0.90%) just before detectable EBV viral load (d242),
continued to increase in expansion frequencies on d299 (4.80%),
and markedly increased on d472 (33.00%) following very high EBV
viral load levels (Figure 3).
In parallel with in vitro amplification, a more sensitive TAME
approach was performed on PBMC from pre-transplant (~13× 106
PBMC) and d32 post transplant (~8× 106 PBMC), and no tetramer+
CD8+ T cells were detected (data not shown), which was not
surprising given limited cells. However, when TAME was performed
on ~40× 106 PBMC from d87, tetramer+ CD8+ T cells were clearly
detected post enrichment (24.38% of CD3+ T cells; Figure 4a) and
single-cell sorted for TCRαβ analysis. Pre-enriched and flowthrough
control samples generated negligible tetramer+ CD8+ T-cell
frequencies of 0.07 and 0.00%. Interestingly, there was a defined
population of tetramer+CD8low/− T cells detected post-enrichment
(10.30%), but were not single-cell sorted with the tetramer+CD8+
T cells for TCRαβ analysis due to sorting limitations. Further
characterization of these post-enriched tetramer+ cells showed that
the tetramer+CD8+ T cells were a mixture of CD45RA+CD27+ and
CD45RA−CD27+ cells and the tetramer+CD8low/− T cells consisted of
Figure 3 GLC-specific CD8+ T-cell response precedes measurable EBV load
in a EBV-negative lung transplant recipient receiving an EBV-positive
allograft. Frequencies of GLC+CD8+ T cells of the total CD8+T-cell
population following expansion and TCRαβ clonotype frequencies were
represented on the left y axis. TCR CDR3αβ sequence details of TRAV5
clonotypes, clonotype A and D are listed in Figure 4f. Patient Tx101’s EBV
viral load (right y axis) was clinically measured in the blood up to d1840
post transplant (closed triangles, EBV viral load=0). EBV serology test
results are indicated by the drop down arrows.
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Figure 4 Early detection of TRAV5-biased GLC-specific CD8+ T cells in patient Tx101. PBMC from patient Tx101 (a) at 87 days post transplant underwent
tetramer-associated magnetic enrichment (TAME). Pre-enriched, post-enriched and the flowthrough fractions were collected and analyzed based on GLC-
tetramer and anti-CD8 antibody staining. Percentages are based on CD3+ T cells. CD3+ T cells, GLC-tetramer+CD8+ and GLC-tetramer+CD8low/− cells from
the post-enriched fraction (b) were phenotypically analyzed based on CD45RA and CD27 expression. Pie charts of paired GLC-specific CD8+ TCRαβ
clonotypes following TAME (d87) (c) or following in vitro expansion (d185, d299 and d472) (d) are shown. Pie chart area shaded in red represent TRAV5
clonotypes. Percentage of TCRαβ clonotypes shared compared to TAME (d87) (bar graph, left y axis) and SDI values (line graph, right y axis) are shown in
e. Frequencies of GLC+CD8+ T cells following expansion and clonotype details are listed in f (ND; not determined).
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a CD45RA−CD27− and CD45RA+CD27− phenotype (Figure 4b). We
speculate that the CD45RAþCD27þ tetramerþCD8þ T cells contain
a population of naive cells, but without CCR7 staining, we cannot
further define the double-positive CD45RAþCD27þ cells as being
truly naive. Based on the mixed CD45RA/CD27 expression profiles, it
is possible that the GLC-specific CD8low T cells detected prior to
clinically indicated EBV primary infection could represent activated
T cells that recently encountered EBV antigen following recent virus
infection. Further, these cells might have recently seen antigen but at
very low, undetectable levels (owing to antiviral therapy and/or
sensitivity of viral load measurements), and possibly at anatomical
sites other than blood.
Diversity of GLC-specific CD8+ TCRαβ repertoire prior to and after
detection of EBV DNA in the blood
In patient Tx101, TCRαβ analysis on d87 post transplant using ex vivo
TAME enrichment for preclinical GLC-specific CD8+ T cells revealed
14 different paired clonotypes with the majority expressing TRAV5
(76%) (Figures 4c and f). Intriguingly, three co-dominant TCRαβ
clonotypes were found (A-26%, B-24% and C-18%), which
consisted of TRAV5/TRAJ31/TRBV20-1/TRBJ1-3 genes with
near-identical CDR3α and CDR3β sequences. Nucleotide sequence
alignments comparing individual cells were identical within the
dominant clonotypes (A–B). Similarly, these near-identical TCRαβ
clonotypes were found in three healthy donors (Figure 1d). The widely
published TRAV5/TRAJ31/TRBV20-1/TRBJ1-2 AS01-TCR was at low
frequency using ex vivo TAME combined with single-cell TCRαβ
analysis (1/34 cells), which may have been undetected using older
cloning strategies.
Next, we examined the longitudinal GLC-specific TCRαβ repertoire
using expanded T-cell lines. TRAV5-biased TCRs were less abundant
on d185 post transplant (41%), which then increased to 90% on d299
post transplant following primary EBV blood viremia before declining
to 63% on d472 post transplant (Figure 3). The decline in
TRAV5 usage was attributed to a non-TRAV5 TCR comprising
TRAV22/TRAJ12/TRBV20-1/TRBJ2-4 genes (clonotype J), which
was dominant on d185 post transplant but subdominant at other
time points (d299 and d472 post transplant). Of interest was the
TCRαβ repertoire dynamics of clonotype A, which was subdominant
on d185 post transplant (26%), but dominant by d299 post transplant
(55%) and up to d472 post transplant (57%) (Figures 3,4d and f),
suggesting that this TCRαβ clonotype might contribute toward
controlling early EBV infection and possibly subsequent reactivations.
Conversely, AS01-TCR was subdominant, peaking at 17% on d299
post transplant (clonotype D; Figures 3,4d and f).
Analysis of clonotype sharing revealed that479% common TCRαβ
clonotypes (range 79.4–83.4%) were used on d185, d299 and d472 as
compared to d87, demonstrating high conservation level of TCRαβ
signatures during the primary detectable blood EBV viremia and
immunosuppression. This occurred despite the fact that different
detection methods were used for GLC-specific CD8+ T cells on d87
(preclinical; TAME) and days 185–472 (in vitro amplification). The
SDI of EBV-specific CD8+ T cells in Tx101 (with the exception of d87
for patient Tx101, as those data were acquired with a different method
and so not directly comparable to the other data sets) was lower at all
time points measured than the SDI of responses in patient Tx98. SDIs
of the responses in patient Tx111 were more variable, but were on
average also higher than those of Tx101. An ANOVA analysis found a
significant difference between the average SDI of the three patients
(P= 0.009), which we followed up by Tukey’s Honest Significant
Difference post-test and found a significant difference between Tx98
and Tx101 (P= 0.007), whereas the P-values for the Tx111-Tx101
comparison and the two non-EBV reactivated patients (Tx98-Tx111
comparison) were not significant (P= 0.088 and P= 0.2, respectively).
Overall, we successfully captured the early GLC-specific TCRαβ
repertoire in an ex vivo immunocompromised setting using TAME
technology. The TCRαβ repertoire was heavily biased for TRAV5 and
was recapitulated in our clinical analysis at later time points, where we
observed a significant dynamic skewing and reorganization in the
order of TCRαβ dominance hierarchy prior to onset of symptoms of
EBV infection and following subsequent EBV reactivations.
Identification of novel paired public CDR3αβ motifs
We have classified four new-paired public TCR CDR3αβ genes and
motifs, in addition to the public AS01-TCR, using single-cell multiplex
reverse transcriptase PCR, which simultaneously analyses CDR3α and
CDR3β chains from a single cell. All TRAV5-TCRs generated from
three healthy donors and three lung transplant patients were collated
to assess which TCRs were identical or near-identical and observed
between donors (Figure 5). As expected, all six donors had
identical (3/6) or near-identical (6/6) TCRs to AS01 and the
paired-motif was generalized as TRAV5/TRAJ31 DXNARL,
TRBV20-1/TRBJ1-2 RXXXGNGY. The other paired motifs identified
in our study were not strictly TRAV5/TRAJ31/TRBV20-1/TRBJ1-2
gene pairings and included TCRαβ gene sequence combinations of:
TRAV5/TRAJ31_DXNARL/TRBV20-1/TRBJ1-3_R*nGNTI (n= 4/6)
(‘*n’ denotes any number of amino-acid residues), TRAV5_S*nGKL/
TRBV29-1/TRBJ1-4_GXXGTNEKL (n= 4/6), TRAV5/TRBV14_
SQSPGGXQ (n= 4/6) and TRAV5/TRBV9/TRBJ2-1_SV*nGXEQ
(n= 3/6). Limited TCRαβ paired and unpaired TCR sequences from
older studies were also collated (Figure 5) to further highlight the
publicly paired motifs, which were not originally identified, possibly
due to the lack of paired TCRαβ analysis, lack of donors or extensive
cloning methodologies. Thus, our data show that the GLC-specific
TCRαβ repertoire included a number of highly prominent and paired
public clonotypes and clonotype motifs that had been previously
underestimated.
DISCUSSION
Human EBV-GLC-specific CD8+ T cells are oligoclonal with an
average of nine unique clonotypes per individual, ranging between
3 and 20 per individual.7,16 In HLA-A*02:01 individuals, GLC-specific
CD8+ TCRαβ clonotypes bearing TRAV5/TRBV20-1 were described
as public, that is, observed across different individuals, and found as
the most dominant pairing.7–9 Here, we quantitatively compared the
abundance and prevalence of public TCRαβ repertoires within the
EBV-GLC-specific CD8+ T cells between healthy individuals and a
longitudinal cohort of lung transplant recipients under immuno-
suppressive conditions. We report, for the first time, the TCRαβ
repertoires of GLC-specific CD8+ T cells in a previously
EBV-seronegative lung transplant patient prior to and following
symptomatic EBV infection and detectable viral load in the blood.
In support, the GLC-specific CD8+ T-cell response was quite
diverse in healthy and immunocompromised individuals, with an
average of 12 TCRαβ clonotypes per individual (range: 7–22
clonotypes). Second, the GLC-specific CD8+ TCR repertoire was
dominated by TRAV5/TRAJ31, which included clusters of paired
public TCRs with either TRBV20-1/TRBJ1-2 or TRBV20-1/
TRBJ1-3 β-chains. Interestingly, rarely were multiple clusters observed
within the same individual. In addition, we found dominant,
previously unrecognized public pairings of TRAV5 with TRBV29-1/
TRBJ1-4, TRBV14 and TRBV9/TRBJ2-1. These pairings were only
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observed in a single individual in other studies8,9 and were not
identified as public TCRαβ pairings previously.
In the EBV-seronegative patient Tx101, whom had received an
HLA-A2−/EBV-seropositive lung allograft, we detected a small
population of GLC-specific CD8+ T cells at pre-transplant (0.37%)
and d32 post transplant (0.10%) following in vitro culture, but not
ex vivo using the TAME methodology. Despite insufficient cell
numbers for TCR analysis and the discrepancy in starting cell numbers
for TAME (8–13× 106 PBMCs compared with 40× 106 PBMCs used
at d87 post transplant), it is possible that naive GLC-specific CD8+
T cells that had never encountered antigen before transplantation.
Interestingly, the successful detection of ex vivo GLC-specific
CD8+ T cells on d87 post transplant, prior to EBV DNA detection
in the blood (d242 post transplant), did reveal two populations
of GLC-specific CD8+ T cells, a tetramer+CD8+ and a tetramerþ
CD8low/− population, and these were phenotypically analyzed based
on CD45RA and CD27 expression. The tetramer+CD8+ population
showed both CD45RA+CD27+ (mainly naive phenotype) and
CD45RA−CD27+ (predominantly memory) phenotypes whereas, the
tetramer+CD8low/− population consisted mainly of a CD45RA−
CD27− phenotype. It is possible that these GLC-specific CD8+
T cells may not be naive and have recently encountered antigen at
low undetectable levels or have been primed at local sites other than
blood. On the other hand, the GLC-specific CD8+ T cells in our
seropositive and asymptomatic donors (D1, D2, D3) and patients
(Tx98 and Tx111) most likely represent memory rather than naive
or effector CD8þ T cells. In support, we have previously
routinely characterized ex vivo GLC-specific CD8þ T cells from a
range of healthy, asymptomatic EBV-positive donors following
TAME (Supplementary Figures 1a and b) and show that those EBV
+CD8+ T cells are predominantly of a CD27þCD45RA− phenotype
(average± s.d.: 74.79%± 9.10%, n= 7) and chiefly represent memory
CD8+ T cells.
Our striking finding was that patient Tx101’s early GLC-specific
CD8+ TCRαβ repertoires were mainly dominated by TRAV5 gene and
consisted of public TCRαβ clonotypes identified in our study (TRAV5/
TRAJ31/TRBV20-1/TRBJ1-3 and TRAV5/TRAJ31/TRBV20-1/TRBJ1-2
public TCRs) and others.8,9 In fact, the majority of dominant and
subdominant GLC-specific CD8+ TCR clonotypes in the preclinical
setting (following TAME) resembled those at later time points leading
to onset of symptomatic EBV infection and at subsequent time points
(bulk T-cell lines), suggesting that these repertoires were established
very early on and perhaps genetically favored upon antigenic exposure.
In support of our hypothesis, a seminal study24 comparing naive and
immune CD8+ TCR repertoires toward dominant influenza peptides
(DbNP366/D
bPA224) in B6 mice showed that the immune TCR
repertoire was directly determined by the naive TCR repertoires.
Our structural analysis of the public AS01-TCR bearing
TRAV5/TRAJ31/TRBV20-1/TRBJ1-2 genes20 exposed how the
combination of these TCR genes were exquisitely designed to bind
to the A2-GLC complex through unique germline residues at crucial
contact points between the TCR and pMHC.20 Similarly, other groups
have found that the GLC-specific CD8+ T cells were highly skewed
toward the TRBV20-1 gene linked to the non-germline aspartate
residue at CDR3β position four.7–9,19 Here, TRBV29-1 was always
associated with glycine at CDR3β position 4 and was replaced with
serine for TRBV14 and TRBV9. Further structural studies are needed
to confirm whether the paired public TCRαβ clusters contain unique
germline and non-germline contact residues that are structurally and
biophysically optimal when engaging the A2-GLC complex. Our
findings are similar to those described earlier for MelanA-specific
Figure 5 TRAV5-biased GLC-specific CD8+ TCRαβ repertoires between
different individuals reveal new public paired genes and motifs. TCRαβ
clonotype sequences from our study were grouped into consensus sequences
and common motifs. Sequences from previously published literature
were collated under each group (X, different amino acid; *n, any number of
amino acid).
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T cells,25 in which we also found a strong V-alpha chain bias
(TRAV12-2), which could pair with different TRBV chains and
structural evidence has shown this is because the TRAV12-2 CDR1
is predominantly responsible for the recognition of the MART-1
pHLA complex. In addition, this study also showed the high frequency
of naive epitope-specific CD8+ T cells directed toward this epitope
owing to a lack of negative selection.25
Longitudinal analysis of the GLC-specific CD8+ T cells in our
three lung transplant patients revealed the relative stability of
the TCRαβ repertoire during early EBV infection, convalescence and
immunosuppression. Especially, in the absence of detectable EBV
reactivation based on viral load testing (patients Tx98 and Tx111), the
GLC-specific TCRαβ repertoires remained stable over time under
immunosuppression. Previously, GLC-specific TCR usage of CD8+
T-cell clones between primary (7–15 days of clinical symptoms in
acute infectious mononucleosis patients) and memory EBV responses
(~26 months later) were compared in three donors.8 Dominant
primary TCR clonotypes were not observed or were less
dominant in the memory response. Conversely, previous longitudinal
studies showed stable EBV-specific TCR repertoires following EBV
infection.12,26 However in these studies, the changes in the TCR
repertoire cannot be interpreted quantitatively due to the biases in
long term in vitro cloning methodologies and bulk RNA TCR analyses.
In our study, we acknowledge that our viral load measurements are
limited by the sensitivity of the assay, yet these methods are standardly
used in our hospitals for clinical diagnostic purposes.
Our recent analysis of antiviral T-cell responses and their TCRαβ
repertoires in lung transplant recipients using limited PBMCs for
T-cell expansion22,27 showed a gradual increase in CMV-specific
CD8+ T cells and a skewing of the TCRαβ repertoire leading up to
CMV reactivation, which then decreased and diversified following
cessation of viremia.22,27 Here, we found a modest increase in the
number of detectable GLC-specific CD8+ T cells after 2 weeks of
culture, which preceded EBV DNA detection in the blood and the
onset of clinical manifestation. In the past, we have also shown
early detection of ex vivo blood and BAL antiviral T cells prior to
measurable levels of viral activation in two primary CMV-mismatched
lung transplant recipients.28 Based on our current and previous
observations, the detection of virus-specific T cells using tetramer
staining seems to be a more sensitive technique to detect early signs of
viral activation from seronegative patients receiving EBV+ donor
grafts, compared with the routine in-house qPCR methods to detect
EBV viral load, which is typically designed for high throughput
screening. This method of viral load measurement has been well
established using plasmid DNA to detect o1–50 EBV genomes from
106 B-lymphocytes or 1 genome from 150 000 cells.29 However,
sensitivity is much lower when extracting DNA from whole-blood
specimens, as other cell populations (that is, mainly neutrophils)
dilute the EBV DNA from B cells. On the other hand, tetramer
staining is highly specific and allows for detection of very rare
antigen-specific T cells, such as naive populations using tetramer
staining and other enrichment strategies. However, we should
acknowledge that there are differences in the timing and frequency
of PBMC collection and viral load measurements (often when
clinically indicated), in which both are sometimes not performed on
the same day owing to logistical constraints.
In conclusion, our findings provide unique insights into the stability
of the GLC-specific TCRαβ repertoire in immunocompromised
transplant patients and that early detection of preclinical GLC-specific
CD8+ T cells and their TCRαβ repertoire dynamics can predict clinical
EBV reactivation in transplant recipients.
METHODS
Human ethics
Experiments were conducted according to the Declaration of Helsinki and
conformed to the NHMRC Code of Practice. All subjects provided written
informed consent and ethics approval was granted from University of
Melbourne, the Alfred Hospital and Monash University Human Research
Ethics Committees.
Subjects and PBMCs
PBMCs were isolated from buffy packs (Australian Red Cross Blood Service;
VIC, Australia). Peripheral blood from HLA-A*02:01-positive bilateral lung
transplant recipients Tx98, Tx111 and Tx101 were collected in heparinized
tubes. Patients received standard triple-therapy immunosuppression and
underwent routine surveillance bronchoscopy at ~ 14, 30, 60, 90, 180, 270
and 365 days post transplant or as indicated.28 PBMC were isolated by
Ficoll-Paque (GE Healthcare, Uppsala, Sweden) density gradient centrifugation
and cryopreserved. HLA molecular typing was performed by the Victorian
Transplantation and Immunogenetics Service (VIC, Australia).
EBV serology and monitoring
EBV IgM and IgG (against early antigen and viral capsid antibody) serology was
determined by the Alfred Hospital Pathology Service where indicated
(VIC, Australia). Patients Tx98 and Tx111 were EBV-seropositive and received
EBV-seronegative donor lung allografts. Patient Tx101 was EBV-seronegative at
the time of transplantation and received an EBV-seropositive donor lung
allograft. Blood EBV viral loads were measured when clinically indicated
(Victorian Infectious Diseases Reference Laboratory and Women’s Centre for
Infectious Diseases, The Royal Women’s Hospital, VIC, Australia) using an
in-house automated MagNA Pure LC (Roche Diagnostics, Indianapolis, IN,
USA) to extract DNA, followed by qPCR to detect EBV, as previously
described.29
Tetramer and generation of T-cell lines
HLA-A*02:01/GLCTLVAML (A2-GLC) monomer (ImmunoID, University of
Melbourne) was tetramerized with streptavidin-phycoerythrin (BD Biosciences,
San Jose, CA, USA). For peptide pulsing, PBMCs were incubated with the GLC
peptide (1–10 μM; Genscript, Piscataway Township, NJ, USA) for 1–1.5 h at
37 °C, then washed twice before priming.30,31 PBMCs were stimulated with
GLC-pulsed autologous PBMCs for 10–13 days (37 °C, 5% CO2) at a 2:1 ratio
in cRF10 media plus 10 U ml− 1 recombinant interleukin-2.32
Paired TCRαβ analysis of EBV-specific CD8+ T cells
T-cell lines were stained with A2-GLC-tetramer-PE for 1h at room
temperature. Cells were washed twice, then stained with anti-CD3-PE-Cy7
(#563423), anti-CD8-PerCP-Cy5.5 (#341051), anti-CD14-APC-Cy7 (#560180),
anti-CD19-APC-Cy7 (#560177) and LIVE/DEAD Fixable NIR (Molecular
Probes, Life Technologies, Eugene, Oregon, USA). Antibodies (their catalog
number in brackets) were from BD Biosciences. CD3+CD8+tetramer+dump−
single-cells were sorted (FACSAria III, BD) into 96-well PCR plates (Eppendorf,
Hamburg, Germany). Analysis of paired CDR3α and CDR3β regions were
performed by multiplex-nested reverse transcriptase PCR, then sequencing of
TCRα and TCRβ products.21,22 Sequences were analyzed according to the
IMGT/V-QUEST web-based tool.33,34
TAME of preclinical EBV-specific CD8+T cells
PBMCs from Tx101 at d87 post transplant were thawed and rested overnight
before incubating with anti-human FcR block (Miltenyi Biotec, Bergisch
Gladbach, Germany) for 15 min on ice. Cells were stained with A2-GLC-
tetramer-PE, washed, incubated with anti-PE microbeads (Miltenyi Biotec)
before passing through LS columns (Miltenyi Biotec) to enrich for tetramer-
stained cells.24,35 Cells were stained with surface antibodies mentioned above, as
well as CD45RA-FITC (#555488) and CD27-APC (#558664) (both from BD
Biosciences) or CD27-AF700 (#56-0279-42, eBioscience, San Diego, CA, USA)
for phenotypic analysis, and then single-cell sorted for TCRαβ analysis.
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Statistical analysis
TCRαβ repertoires from patients Tx98, Tx101, and Tx111 were analyzed by
SDI using the ‘vegan’ package in R. An ANOVA with Tukey’s honest significant
difference as a post-test was run on the SDIs obtained, with the P-values
indicated.36,37 In our previous study,22420 TCRαβ sequence pairs per sample
have been sufficient to ensure adequate power for statistical analysis.
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